| Document |
Document Title |
|
WO/2006/117359A1 |
The invention relates to a crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((Sj-tetrahydrofura
n-3-yloxy)-benzyl]-benzene, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.
|
|
WO/2006/108802A1 |
Preparation of cyclic esters by hydrogenation of a carbonyl group in at least one anhydride radical -C(O)-O-C(O)- of a cyclic dicarboxylic or polycarboxylic anhydride by means of hydrogen in the presence of a homogeneous noble metal cata...
|
|
WO/2006/108591A1 |
The present invention relates to l H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as AMPA-receptor ligands, in particular for the treatment of epilepsy or schiz...
|
|
WO/2006/104387A1 |
One aspect of the present invention is concerned with a composition containing: (A) at least 10 μg of particular substituted pyrroles per kg of dry matter; and (B) at least 100 mg per kg of dry matter of a pyranone selected from the gro...
|
|
WO/2006/101144A1 |
[PROBLEMS] To provide a charge control agent, which has a practical level of negative charge imparting properties, is colorless and a light color and can be used in a color toner, can realize good stability against an environmental chang...
|
|
WO/2006/100100A1 |
The invention relates to tetrahydronaphthalene derivatives of general formula (I), to a method for their production and to their use as anti-inflammatory agents.
|
|
WO/2006/098959A1 |
The present invention is concerned with novel processes for the preparation of (R)-4,4-dimethoxy–pyran-3-ol. This compound is useful as an intermediate in the synthesis of compounds which possess pharmacological activity including CCR2...
|
|
WO/2006/098308A1 |
An anthranilic acid derivative represented by the general formula below or a salt thereof: wherein R1 and R2 independently represent a hydrogen atom or the like; R3 represents a phenyl, cycloalkyl or bicyclic heterocyclic group which may...
|
|
WO/2006/095475A1 |
[PROBLEMS] To provide a compound which has a satisfactory catalytic activity for use as a catalyst carrying a metal belonging to the chromium group therein, which can be separated from a desired product readily and which is reusable. [ME...
|
|
WO/2006/095020A1 |
Compounds of the general formula (I) in which the meanings of the substituents R1 and R2 are as stated in claim 1, have renin-inhibiting properties and can be used as medicines.
|
|
WO/2006/093336A1 |
Disclosed is a fibronectin gene transcription inhibitor composition or the like characterized by containing a cinnamoyl compound represented by the formula (I) below and an inert carrier. (I)
|
|
WO/2006/092049A1 |
The invention comprises compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions containing the compounds or prodrugs of the compounds. The invention also comprises animal models and m...
|
|
WO/2006/089872A1 |
Glucopyranosyl-substituted (hetero)arylethynyl-benzene derivatives of the general formula (I) where the groups R1 to R6 as well as R7a, R7b, R7c are defined according to claim 1, including the tautomers, the stereoisomers thereof, the mi...
|
|
WO/2006/089008A2 |
The present invention relates to methods for the preparation of 3,3-dialky 4- chromanones, and particularly to the preparation of 6-fluoro-3,3-dimethyl-2,3-dihydro- 4H-chromen-4-one and 3,3-dimethyl-2,3-dihydro-4H-chromen-4-one. In some ...
|
|
WO/2006/085510A1 |
A remedy for IBS comprising, as the active ingredient, a dual antagonist for 5-HT2B and 5-HT7 receptors which shows selective binding affinities to 5-HT2B and 5-HT7 receptors. The above-described medicinal composition is superior in the ...
|
|
WO/2006/083271A2 |
The invention provides certain acylthiourea derivatives and pharmaceutically acceptable salts thereof. These compounds possess potent antiviral activity. The invention particularly provides compounds that are potent and/or selective inhi...
|
|
WO/2006/082594A1 |
An improved method for manufacture of simvastatin of formula (I) in high purity. The process for preparation of compound (I) comprises Formula I the steps of agitating a compound of formula (II), Formula II wherein R is hydrogen, NH4+ or...
|
|
WO/2006/082010A1 |
Provided herein are compounds of the formula (I), as well as pharmaceutically acceptable salts thereof, wherein R1, R2, R2´, R3, R4, R5 and X are as defined in the specification and claims. These compounds, and the pharmaceutical compos...
|
|
WO/2006/080339A1 |
A process for producing 5-chloro-2,4-dihydroxypyridine of Formula (1) comprising the steps of reacting a 5-chloro-1,3-dioxin-4-on derivative (2) represented by Formula (2) with a ketene acetal derivative (3) represented by Formula (3) to...
|
|
WO/2006/072963A1 |
The application describes a new process for preparing Simvastatin from Lovastatin amine salts in three steps. Lovastatin was hydrolysed to acid form and then isolated in the form of amine salt like cyclopropyl or t-octyl amine etc. The s...
|
|
WO/2006/070383A1 |
The present invention relates to a process for the synthesis of racemic nerol oxide i.e. 3,6-dihydro-4-methyl-2-[2-methyl-1-propenyl)-2H-pyran from monoterpene alcohol nerol i.e. cis-3,7-dimethylocta-2,6-diene-1-ol.
|
|
WO/2006/068213A1 |
A glycine derivative which is, e.g., the following compound (Chemical formula (1)). It is highly effective in the treatment and prevention of inflammatory bowel diseases. Compared to conventional compounds, the compound is excellent in a...
|
|
WO/2006/064179A1 |
There is provides a process for the preparation of a compound of formula (7): wherein R is an optionally substituted hydrocarbyl group or an optionally substituted heterocyclic group; provides that R is not a compound of Formula (a): whe...
|
|
WO/2006/062110A1 |
A compound represented by the formula (I): [wherein R1 represents C3-9 branched alkyl; R2 represents, e.g., linear or branched, C2-9 alkyl optionally substituted by halogen, etc.; and X represents oxygen, etc.] (provided that the followi...
|
|
WO/2006/062211A1 |
The invention provides a production process of a tetrahydropyran compound, characterized by allowing 3,4-dihydro-2-alkoxy-2H-pyran compound or tetrahydro-2-alkoxy-2H-pyran compound which can be easily prepared through reaction between ac...
|
|
WO/2006/059346A2 |
This invention describes a process for lactonization of simvastatin hydroxyacid or its salts that avoids use of strong corrosive acids and drastic heat conditions. Specifically the process can be carried out at moderate temperature resul...
|
|
WO/2006/055472A2 |
Synthetic discodermolide analogs having utility as antiproliferative agents, having a structure represented by formula A, where RA through RE and XA are as difined herein.
|
|
WO/2006/054688A1 |
A process for producing tetrahydropyran-4-carboxylic acid of the formula: (1) characterized by hydrolytic reaction, in the presence of an acid, of a 4-cyanotetrahydropyran-4-carboxylic acid compound of the formula: (2) wherein R is a hyd...
|
|
WO/2006/045554A1 |
The present invention relates to compounds having the general formula (I) with the definitions of A, X, R1-R6 given below, and/or a salt or ester thereof. Furthermore the invention relates to the use of said compounds for the treatment o...
|
|
WO/2006/038522A1 |
Liquid crystal compounds having general physical properties necessary to compounds, low viscosity, proper optical anisotropy, proper anisotropy of permittivity, and excellent compatibility with other liquid crystal compounds; liquid crys...
|
|
WO/2006/038606A1 |
Disclosed are a compound represented by the formula (I) below, a pharmaceutically acceptable salt thereof, a solvate of those, and a pharmaceutical composition containing such a compound. (In the formula, X1 represents N or CR2; X2 repre...
|
|
WO/2006/038594A1 |
An N-type calcium channel inhibitor which contains a compound having N-type calcium channel inhibitory activity and represented by the general formula (I): (wherein the symbols are the same as defined in the description), a salt thereof,...
|
|
WO/2006/035295A1 |
The invention relates to a process for the preparation of lovastatin. More particularly, it relates to the preparation of lovastatin substantially free of dihydrolovastatin. The invention also relates to pharmaceutical compositions that ...
|
|
WO/2006/034641A1 |
The present invention discloses a process for producing Simvastatin and intermediate thereof. The present invention uses inexpensive and available reagent, its condition is mild, and it leaves out the protective and deprotective steps wh...
|
|
WO/2006/034004A2 |
The present invention is directed to a process for preparing certain cysteine protease inhibitors.
|
|
WO/2006/030807A1 |
A compound represented by the formula (I), which has antiviral activity, especially HIV integrase inhibitory activity, a pharmaceutically acceptable salt of the compound, or a solvate of either; and a medicine, especially an anti-HIV dru...
|
|
WO/2006/027344A2 |
Compounds of a certain formula 1, in which R1, R2 and R3 have the meanings indicated in the description, are novel effective PDE4 inhibitors.
|
|
WO/2006/028972A2 |
Mercaptoamide compounds, represented by Formulas (IA), (IB), (IIA), and (IIB): or a pharmaceutically acceptable salt thereof, inhibit histone deacetylase enzyme and are useful for the treatment and/or prevention of various infections, ca...
|
|
WO/2006/028038A1 |
[PROBLEMS] An MMP-13 inhibitor is desired because inhibiting MMP-13 activity is thought to greatly contribute to the alleviation of or prevention of the progress of diseases attributable or relating to the activity, especially osteoarthr...
|
|
WO/2006/028523A2 |
The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula...
|
|
WO2005063239A9 |
The invention relates to amid compounds of general formula (I), wherein groups and residuals A, B, b, W, X, Y, Z, R
|
|
WO/2006/021663A1 |
The invention relates, in particular to a tetrahydropyran(on) compound which is substituted in position beta with respect to a cycle oxygen of formula (I), wherein a substituent R is a linear alkyl radical in C2:C10 including,(CH3)2CH- o...
|
|
WO/2006/018725A1 |
The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of H...
|
|
WO/2006/018150A1 |
The invention relates to D-xylopyranosyl-phenyl-substituted cyclene of general formula (I), wherein radicals R1 to R6, X, Z, Cy and R7a, R7b, R7c which are defined in claim 1, have an inhibiting effect on the sodium-dependent SGLT glucos...
|
|
WO/2006/016178A1 |
A process for the production of compounds comprising the enantioselective hydrogenation of 2-substituted acrylic acid derivatives.
|
|
WO/2006/013920A1 |
This invention provides a 2-substituted-3-(4-tetrahydropyranyl)-3-oxopropanoic ester represented by general formula (1) wherein Y represents a halogen atom or an acyloxy group, and R represents a hydrocarbon group, and a process for prod...
|
|
WO/2006/014024A1 |
A preventive and/or therapeutic agent for psychoneurotic diseases, comprising an EP3 antagonist represented by the general formula: (I) (wherein the meanings of characters are defined in the description). This compound has an antagonisti...
|
|
WO/2006/012227A2 |
The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor MR, and pharmaceutical compositions thereof. The compounds of the invention can be useful in the tr...
|
|
WO/2006/012135A1 |
Quaternary salt compounds of Formula (I) or pharmaceutically acceptable forms thereof, which are CCR2 antagonists and are useful in preventing, treating or ameliorating CCR2 mediated inflammatory syndromes, disorders or diseases in a sub...
|
|
WO/2006/010557A1 |
The invention relates to D-glucopyranosyl phenyl-substituted cyclene of general formula (I), in which: radicals R1 to R6, Z, Cy as well as R7a, R7b, R7c, R7d are defined as in Claim 1. The inventive compounds have an inhibitory effect up...
|
